Cagrilintide
Long-acting amylin analog
An amylin receptor agonist studied alone and alongside GLP-1 analogs for satiety and body weight.
How it works
Activates amylin and calcitonin receptors in the area postrema, slowing gastric emptying and reinforcing meal-ending satiety signals through a pathway separate from GLP-1.
What research has shown
Monotherapy studies report about 10% weight reduction at 26 weeks, with larger reductions when combined with semaglutide in combination trials.
Reported ranges in the literature
Low end
0.3 mg weekly
Optimal
1.2 to 2.4 mg weekly
High end
4.5 mg weekly in dose-ranging work
Frequency reported in the literature: Once weekly
Protocol duration and pairing
Typical study duration
20 to 68 weeks depending on whether it is studied alone or with an incretin.
Best paired with
The canonical partner compound in this catalog: amylin agonism complements incretin appetite signaling through a separate pathway.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.